Literature DB >> 33445810

Cytokines and Chemokines in SARS-CoV-2 Infections-Therapeutic Strategies Targeting Cytokine Storm.

Alexandra Pum1, Maria Ennemoser1, Tiziana Adage2, Andreas J Kungl1,3.   

Abstract

The recently identified severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, the cause of coronavirus disease (COVID-19) and the associated ongoing pandemic, frequently leads to severe respiratory distress syndrome and pneumonia with fatal consequences. Although several factors of this infection and its consequences are not completely clear, the presence and involvement of specific chemokines is undoubtedly crucial for the development and progression of COVID-19. Cytokine storm and the often-resulting cytokine release syndrome (CRS) are pathophysiological hallmarks in COVID-19 infections related to its most severe and fatal cases. In this hyperinflammatory event, chemokines and other cytokines are highly upregulated and are therefore not fulfilling their beneficial function in the host response anymore but causing harmful effects. Here, we present the recent views on the involvement of chemokines and selected cytokines in COVID-19 and the therapeutics currently in clinical development targeting or interfering with them, discussing their potentials in the treatment of COVID-19 infections.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; chemokines; coronavirus; cytokine storm

Mesh:

Substances:

Year:  2021        PMID: 33445810      PMCID: PMC7828218          DOI: 10.3390/biom11010091

Source DB:  PubMed          Journal:  Biomolecules        ISSN: 2218-273X


  102 in total

1.  Augmented expression of secondary lymphoid tissue chemokine and EBI1 ligand chemokine in Crohn's disease.

Authors:  D Kawashima; N Oshitani; Y Jinno; K Watanabe; S Nakamura; K Higuchi; T Arakawa
Journal:  J Clin Pathol       Date:  2005-10       Impact factor: 3.411

2.  CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn's disease.

Authors:  K A Papadakis; J Prehn; S T Moreno; L Cheng; E A Kouroumalis; R Deem; T Breaverman; P D Ponath; D P Andrew; P H Green; M R Hodge; S W Binder; S R Targan
Journal:  Gastroenterology       Date:  2001-08       Impact factor: 22.682

3.  Cytokine release syndrome in COVID-19: Innate immune, vascular, and platelet pathogenic factors differ in severity of disease and sex.

Authors:  Aaron C Petrey; Fares Qeadan; Elizabeth A Middleton; Irina V Pinchuk; Robert A Campbell; Ellen J Beswick
Journal:  J Leukoc Biol       Date:  2020-09-15       Impact factor: 4.962

4.  An inflammatory cytokine signature predicts COVID-19 severity and survival.

Authors:  Diane Marie Del Valle; Seunghee Kim-Schulze; Hsin-Hui Huang; Noam D Beckmann; Sharon Nirenberg; Bo Wang; Yonit Lavin; Talia H Swartz; Deepu Madduri; Aryeh Stock; Thomas U Marron; Hui Xie; Manishkumar Patel; Kevin Tuballes; Oliver Van Oekelen; Adeeb Rahman; Patricia Kovatch; Judith A Aberg; Eric Schadt; Sundar Jagannath; Madhu Mazumdar; Alexander W Charney; Adolfo Firpo-Betancourt; Damodara Rao Mendu; Jeffrey Jhang; David Reich; Keith Sigel; Carlos Cordon-Cardo; Marc Feldmann; Samir Parekh; Miriam Merad; Sacha Gnjatic
Journal:  Nat Med       Date:  2020-08-24       Impact factor: 53.440

Review 5.  The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19.

Authors:  Lauren A Callender; Michelle Curran; Stephanie M Bates; Maelle Mairesse; Julia Weigandt; Catherine J Betts
Journal:  Front Immunol       Date:  2020-08-11       Impact factor: 7.561

6.  Tocilizumab for the treatment of severe coronavirus disease 2019.

Authors:  Rand Alattar; Tawheeda B H Ibrahim; Shahd H Shaar; Shiema Abdalla; Kinda Shukri; Joanne N Daghfal; Mohamed Y Khatib; Mohamed Aboukamar; Mohamed Abukhattab; Hussam A Alsoub; Muna A Almaslamani; Ali S Omrani
Journal:  J Med Virol       Date:  2020-05-10       Impact factor: 2.327

Review 7.  Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy.

Authors:  Paola Toniati; Simone Piva; Marco Cattalini; Emirena Garrafa; Francesca Regola; Francesco Castelli; Franco Franceschini; Paolo Airò; Chiara Bazzani; Eva-Andrea Beindorf; Marialma Berlendis; Michela Bezzi; Nicola Bossini; Maurizio Castellano; Sergio Cattaneo; Ilaria Cavazzana; Giovanni-Battista Contessi; Massimo Crippa; Andrea Delbarba; Elena De Peri; Angela Faletti; Matteo Filippini; Matteo Filippini; Micol Frassi; Mario Gaggiotti; Roberto Gorla; Michael Lanspa; Silvia Lorenzotti; Rosa Marino; Roberto Maroldi; Marco Metra; Alberto Matteelli; Denise Modina; Giovanni Moioli; Giovanni Montani; Maria-Lorenza Muiesan; Silvia Odolini; Elena Peli; Silvia Pesenti; Maria-Chiara Pezzoli; Ilenia Pirola; Alessandro Pozzi; Alessandro Proto; Francesco-Antonio Rasulo; Giulia Renisi; Chiara Ricci; Damiano Rizzoni; Giuseppe Romanelli; Mara Rossi; Massimo Salvetti; Francesco Scolari; Liana Signorini; Marco Taglietti; Gabriele Tomasoni; Lina-Rachele Tomasoni; Fabio Turla; Alberto Valsecchi; Davide Zani; Francesco Zuccalà; Fiammetta Zunica; Emanuele Focà; Laura Andreoli; Nicola Latronico
Journal:  Autoimmun Rev       Date:  2020-05-03       Impact factor: 9.754

8.  The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19.

Authors:  Alessandro Gozzetti; Enrico Capochiani; Monica Bocchia
Journal:  Leukemia       Date:  2020-09-02       Impact factor: 11.528

9.  Pathological findings of COVID-19 associated with acute respiratory distress syndrome.

Authors:  Zhe Xu; Lei Shi; Yijin Wang; Jiyuan Zhang; Lei Huang; Chao Zhang; Shuhong Liu; Peng Zhao; Hongxia Liu; Li Zhu; Yanhong Tai; Changqing Bai; Tingting Gao; Jinwen Song; Peng Xia; Jinghui Dong; Jingmin Zhao; Fu-Sheng Wang
Journal:  Lancet Respir Med       Date:  2020-02-18       Impact factor: 30.700

10.  Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19.

Authors:  Yang Yang; Chenguang Shen; Jinxiu Li; Jing Yuan; Jinli Wei; Fengmin Huang; Fuxiang Wang; Guobao Li; Yanjie Li; Li Xing; Ling Peng; Minghui Yang; Mengli Cao; Haixia Zheng; Weibo Wu; Rongrong Zou; Delin Li; Zhixiang Xu; Haiyan Wang; Mingxia Zhang; Zheng Zhang; George F Gao; Chengyu Jiang; Lei Liu; Yingxia Liu
Journal:  J Allergy Clin Immunol       Date:  2020-04-29       Impact factor: 14.290

View more
  27 in total

1.  Implications for Systemic Approaches to COVID-19: Effect Sizes of Remdesivir, Tocilizumab, Melatonin, Vitamin D3, and Meditation.

Authors:  Ryan D Castle; Michelle A Williams; William C Bushell; J Adam Rindfleisch; Christine Tara Peterson; James Marzolf; Kimberly Brouwer; Paul J Mills
Journal:  J Inflamm Res       Date:  2021-09-22

2.  The interplay between lncRNAs, RNA-binding proteins and viral genome during SARS-CoV-2 infection reveals strong connections with regulatory events involved in RNA metabolism and immune response.

Authors:  Francisco J Enguita; Ana Lúcia Leitão; J Tyson McDonald; Viktorija Zaksas; Saswati Das; Diego Galeano; Deanne Taylor; Eve Syrkin Wurtele; Amanda Saravia-Butler; Stephen B Baylin; Robert Meller; D Marshall Porterfield; Douglas C Wallace; Jonathan C Schisler; Christopher E Mason; Afshin Beheshti
Journal:  Theranostics       Date:  2022-05-09       Impact factor: 11.600

Review 3.  Inflammatory reflex disruption in COVID-19.

Authors:  Khalil Hajiasgharzadeh; Mahdi Jafarlou; Behzad Mansoori; Narges Dastmalchi; Behzad Baradaran; Alireza Khabbazi
Journal:  Clin Exp Neuroimmunol       Date:  2022-04-29

Review 4.  COVID-19 Vasculopathy: Mounting Evidence of an Indirect Mechanism of Endothelial Injury.

Authors:  Roberto F Nicosia; Giovanni Ligresti; Nunzia Caporarello; Shreeram Akilesh; Domenico Ribatti
Journal:  Am J Pathol       Date:  2021-05-23       Impact factor: 4.307

Review 5.  Role of Inflammatory Cytokines in COVID-19 Patients: A Review on Molecular Mechanisms, Immune Functions, Immunopathology and Immunomodulatory Drugs to Counter Cytokine Storm.

Authors:  Ali A Rabaan; Shamsah H Al-Ahmed; Javed Muhammad; Amjad Khan; Anupam A Sule; Raghavendra Tirupathi; Abbas Al Mutair; Saad Alhumaid; Awad Al-Omari; Manish Dhawan; Ruchi Tiwari; Khan Sharun; Ranjan K Mohapatra; Saikat Mitra; Muhammad Bilal; Salem A Alyami; Talha Bin Emran; Mohammad Ali Moni; Kuldeep Dhama
Journal:  Vaccines (Basel)       Date:  2021-04-29

6.  Clinical Features and Outcomes of Coronavirus Disease 2019 Among People With Human Immunodeficiency Virus in the United States: A Multicenter Study From a Large Global Health Research Network (TriNetX).

Authors:  George A Yendewa; Jaime Abraham Perez; Kayla Schlick; Heather Tribout; Grace A McComsey
Journal:  Open Forum Infect Dis       Date:  2021-06-01       Impact factor: 3.835

Review 7.  Diverse Immunological Factors Influencing Pathogenesis in Patients with COVID-19: A Review on Viral Dissemination, Immunotherapeutic Options to Counter Cytokine Storm and Inflammatory Responses.

Authors:  Ali A Rabaan; Shamsah H Al-Ahmed; Mohammed A Garout; Ayman M Al-Qaaneh; Anupam A Sule; Raghavendra Tirupathi; Abbas Al Mutair; Saad Alhumaid; Abdulkarim Hasan; Manish Dhawan; Ruchi Tiwari; Khan Sharun; Ranjan K Mohapatra; Saikat Mitra; Talha Bin Emran; Muhammad Bilal; Rajendra Singh; Salem A Alyami; Mohammad Ali Moni; Kuldeep Dhama
Journal:  Pathogens       Date:  2021-05-07

Review 8.  Boswellic acids/Boswellia serrata extract as a potential COVID-19 therapeutic agent in the elderly.

Authors:  Adel A Gomaa; Hamdy S Mohamed; Rasha Bakheet Abd-Ellatief; Mohamed A Gomaa
Journal:  Inflammopharmacology       Date:  2021-07-05       Impact factor: 4.473

Review 9.  Eosinophils and COVID-19: diagnosis, prognosis, and vaccination strategies.

Authors:  Helene F Rosenberg; Paul S Foster
Journal:  Semin Immunopathol       Date:  2021-03-16       Impact factor: 9.623

10.  Profile of Circulatory Cytokines and Chemokines in Human Coronaviruses: A Systematic Review and Meta-Analysis.

Authors:  Ayat Zawawi; Abdallah Y Naser; Hassan Alwafi; Faisal Minshawi
Journal:  Front Immunol       Date:  2021-05-05       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.